Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 327

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

Open access
Burdett, Sarah, Boevé, Liselotte M., Ingleby, Fiona C., Fisher, David J., Rydzewska, Larysa H., Vale, Claire L., van Andel, George, Clarke, Noel W., Hulshof, Maarten C., James, Nicholas D., Parker, Christopher C., Parmar, Mahesh K., Sweeney, Christopher J., Sydes, Matthew R., Tombal, Bertrand, Verhagen, Paul C., Tierney, Jayne F. · 2019 · European Urology

Abstract

Background Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). Objective To systematically review trials of prostate radiotherapy. Design, setting, and participants Using a prospective framework (framework for adaptive meta-analysis [FAME]), we prespecified methods before any trial results were known. We searched extensively for eligible trials and asked investigators when results would be available. We could then anticipate that a definitive meta-analysis of the effects of prostate radiotherapy was possible. We obtained prepublication, unpublished, and harmonised results from investigators. Intervention We included trials that randomised men to prostate radiotherapy and androgen deprivation therapy (ADT) or ADT only. Outcome measurements and statistical analysis Hazard ratios (HRs) for the effects of prostate radiotherapy on survival, progression-free survival (PFS), failure-free survival (FFS), biochemical progression, and subgroup interactions were combined using fixed-effect meta-analysis. Results and limitations We identified one ongoing (PEACE-1) and two completed (HORRAD and STAMPEDE) eligible trials. Pooled results of the latter (2126 men; 90% of those eligible) showed no overall improvement in survival (HR = 0.92, 95% confidence interval [CI] 0.81–1.04, p = 0.195) or PFS (HR = 0.94, 95% CI 0.84–1.05, p = 0.238) with prostate radiotherapy. There was an overall improvement in biochemical progression (HR = 0.74, 95% CI 0.67–0.82, p = 0.94 × 10 −8 ) and FFS (HR = 0.76, 95% CI 0.69–0.84, p = 0.64 × 10 −7 ), equivalent to ∼10% benefit at 3 yr. The effect of prostate radiotherapy varied by metastatic burden—a pattern consistent across trials and outcome measures, including survival (<5, ≥5; interaction HR = 1.47, 95% CI 1.11–1.94, p = 0.007). There was 7% improvement in 3-yr survival in men with fewer than five bone metastases. Conclusions Prostate radiotherapy should be considered for men with mHSPC with a low metastatic burden. Patient summary Prostate cancer that has spread to other parts of the body (metastases) is usually treated with hormone therapy. In men with fewer than five bone metastases, addition of prostate radiotherapy helped them live longer and should be considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2019.02.003

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 327

Metadata

Authors
Burdett, S., Boevé, L. M., Ingleby, F. C., Fisher, D. J., Rydzewska, L. H., Vale, C. L., van Andel, G., Clarke, N. W., Hulshof, M. C., James, N. D., Parker, C. C., Parmar, M. K., Sweeney, C. J., Sydes, M. R., Tombal, B., Verhagen, P. C., & Tierney, J. F.
Venue
European Urology
Publisher
Elsevier BV
Published
2019-07
Volume
76
Issue
1
Pages
115-124
ISSN
0302-2838 (ISSN-L)
OpenAlex
W2919810454
Cited by
327
References
20
FWCI
9.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1016/j.eururo.2019.02.003
The paper
Burdett, S., Boevé, L. M., Ingleby, F. C., Fisher, D. J., Rydzewska, L. H., Vale, C. L., van Andel, G., Clarke, N. W., Hulshof, M. C., James, N. D., Parker, C. C., Parmar, M. K., Sweeney, C. J., Sydes, M. R., Tombal, B., Verhagen, P. C., & Tierney, J. F. (2019). Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. European Urology. https://doi.org/10.1016/j.eururo.2019.02.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.